BACKGROUND AND AIM: The purpose of this study was to evaluate both the predictive value of metabolic syndrome (MS) on no-reflow phenomenon and 30-day clinical outcomes on patients undergoing primary percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS: One hundred and twelve consecutive patients (mean age 57+/-11 years, 94 male) with acute STEMI treated with primary PCI were analysed prospectively. Sum of ST-segment elevation was obtained immediately before and 60 min after the restoration of TIMI-3 flow. The difference between two measurements was accepted as the amount of ST-segment resolution and was expressed as summation operatorSTR. summation operatorSTR<50% was accepted as ECG sign of no-reflow phenomenon. Metabolic syndrome was defined based on Adult Treatment Panel-III criteria. The no-reflow was found in 22.3% of the entire group and was significantly higher in patients with MS than those without MS (43.7% vs. 13.7%, p<0.001). There was no significant difference in no-reflow between patients who had both MS and diabetes mellitus (DM) and patients who had MS but not DM (42.5% vs. 50%, respectively; p>0.05). CONCLUSION: The presence of MS may play an important role in the occurrence of no- reflow in STEMI treated with primary PCI.
BACKGROUND AND AIM: The purpose of this study was to evaluate both the predictive value of metabolic syndrome (MS) on no-reflow phenomenon and 30-day clinical outcomes on patients undergoing primary percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS: One hundred and twelve consecutive patients (mean age 57+/-11 years, 94 male) with acute STEMI treated with primary PCI were analysed prospectively. Sum of ST-segment elevation was obtained immediately before and 60 min after the restoration of TIMI-3 flow. The difference between two measurements was accepted as the amount of ST-segment resolution and was expressed as summation operatorSTR. summation operatorSTR<50% was accepted as ECG sign of no-reflow phenomenon. Metabolic syndrome was defined based on Adult Treatment Panel-III criteria. The no-reflow was found in 22.3% of the entire group and was significantly higher in patients with MS than those without MS (43.7% vs. 13.7%, p<0.001). There was no significant difference in no-reflow between patients who had both MS and diabetes mellitus (DM) and patients who had MS but not DM (42.5% vs. 50%, respectively; p>0.05). CONCLUSION: The presence of MS may play an important role in the occurrence of no- reflow in STEMI treated with primary PCI.
Authors: Ryanne P Betgem; Guus A de Waard; Robin Nijveldt; Aernout M Beek; Javier Escaned; Niels van Royen Journal: Nat Rev Cardiol Date: 2014-11-18 Impact factor: 32.419
Authors: Owen Igbinosa; Ahmed Brgdar; Joseph Asemota; Mohamed E Taha; Jin Yi; Anthony Lyonga Ngonge; Swati Vanaparthy; Raccquel Hammonds; Joseph Talbet; Diannemarie Omire-Mayor; Julius Ngwa; Muhammad Rizwan; Mehrotra Prafulla; Isaac Opoku Journal: Cureus Date: 2022-05-02
Authors: G de Simone; R B Devereux; M Chinali; M J Roman; E T Lee; H E Resnick; B V Howard Journal: Nutr Metab Cardiovasc Dis Date: 2008-07-31 Impact factor: 4.222
Authors: Danijela Trifunovic; Sanja Stankovic; Dragana Sobic-Saranovic; Jelena Marinkovic; Marija Petrovic; Dejan Orlic; Branko Beleslin; Marko Banovic; Bosiljka Vujisic-Tesic; Milan Petrovic; Ivana Nedeljkovic; Jelena Stepanovic; Ana Djordjevic-Dikic; Milorad Tesic; Nina Djukanovic; Olga Petrovic; Olga Vasovic; Emilija Nestorovic; Jelena Kostic; Arsen Ristic; Miodrag Ostojic Journal: Cardiovasc Diabetol Date: 2014-04-05 Impact factor: 9.951
Authors: Roman Pfister; Samuel Lee; Kathrin Kuhr; Frank Baer; Wolfgang Fehske; Hans-Wilhelm Hoepp; Stephan Baldus; Guido Michels Journal: PLoS One Date: 2016-06-03 Impact factor: 3.240